{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:14Z","timestamp":1793747054829,"version":"4.6.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021049","name":"Imunon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/13543784.2026.2636926","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:01:01Z","timestamp":1772722861000},"page":"191-202","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings"],"prefix":"10.1080","volume":"35","author":[{"given":"Premal H.","family":"Thaker","sequence":"first","affiliation":[{"name":"Washington University School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy R.","family":"Lindborg","sequence":"additional","affiliation":[{"name":"Imunon","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Limon","sequence":"additional","affiliation":[{"name":"Imunon","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[{"name":"Imunon","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Froedtert Hospital & Medical College of Wisconsin","place":["Milwaukee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khursheed","family":"Anwer","sequence":"additional","affiliation":[{"name":"Imunon","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00881-3"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102945"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.022"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3"},{"key":"e_1_3_3_10_1","unstructured":"GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer [Internet]. News Release. GSK. 2024 [cited 2024 Dec 20]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer\/"},{"key":"e_1_3_3_11_1","volume-title":"Durvalumab plus paclitaxel\/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1\/BRCA2 mutation: updated results from DUO-O\/ENGOT-OV46\/GOG-3025 trial","author":"Harter PWP","year":"2024","unstructured":"Harter PWP, Okamoto A, Reuss A, et al. Durvalumab plus paclitaxel\/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1\/BRCA2 mutation: updated results from DUO-O\/ENGOT-OV46\/GOG-3025 trial. San Diego (CA): Society of Gynecological Oncology; 2024 Mar 14\u201316."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667464"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.578"},{"key":"e_1_3_3_14_1","volume-title":"StatPearls [Internet]","author":"Arora T","year":"2025","unstructured":"Arora T, Mullangi S, Vadakekut ES, et al. Epithelial ovarian cancer. 2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. PMID: 33620837."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00640-8"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1328651"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28389-3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1356"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2198185"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0423"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01011-2"},{"issue":"3","key":"e_1_3_3_26_1","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3(3):409\u2013417.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-66"},{"issue":"7","key":"e_1_3_3_28_1","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard JP","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541\u20132548.","journal-title":"Blood"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.70000"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300900"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00053"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.05.040"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01917-7"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04105-0"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.03.571"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.159"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.07.081"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.001"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010760"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0360"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.22.00103"},{"issue":"1","key":"e_1_3_3_42_1","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta E","year":"1998","unstructured":"Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res. 1998;4(1):75\u201385.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"e_1_3_3_43_1","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer RJ","year":"1998","unstructured":"Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 1998;4(5):1183\u20131191.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0122"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080063"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605274"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.09.005"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2657"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1433"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0817-1"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10712"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903210"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006991"},{"key":"e_1_3_3_54_1","unstructured":"KEYTRUDA \u00ae (pembrolizumab) plus chemotherapy followed by maintenance with LYNPARZA \u00ae (olaparib) with or without bevacizumab demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone [Internet]. 2024 Sep 12. Available from: https:\/\/www.merck.com\/news\/merck-announces-phase-3-keylynk-001-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-advanced-epithelial-ovarian-cancer\/"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00671"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.013"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243915"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2636926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:49:33Z","timestamp":1773402573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2636926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/13543784.2026.2636926"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2636926","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}